IDNA vaccines and methods for using the same
US8691563B2 · kind B2 · utility
11Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2009 |
| Grant date | Apr 8, 2014 |
| Priority date | — |
| Expiry date | Mar 27, 2030 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.